Filing Flows › ADC Therapeutics SA (ADCT) › Q4 2024
ADC Therapeutics SA (ADCT) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 27, 2025
ADC Therapeutics SA (ADCT) reported revenue of $16.9M for the fourth quarter 2024 (Q4 2024), +0.7% from a year earlier and -8% from the quarter before. Operating margin was -191.8%, net loss $30.7M (181.7% of revenue).
ADC Therapeutics SA, Q4 2024: revenue $16.9M (+0.7% year over year), operating margin -191.8%, net loss $30.7M, operating cash flow −$21.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.9M | -8% | +0.7% |
| Operating profit | −$32.4M | — | — |
| Net earnings | −$30.7M | — | — |
| Operating cash flow | −$21.9M | — | — |
What changed
Revenue was $16.9M in Q4 2024, up 1% year over year and down 8% from the previous quarter.
Operating costs exceeded revenue by $32.4M, an operating margin of -191.8%. Total costs fell 13% while revenue rose 1%. The fastest-growing cost line was Other operating costs (+43%). The quarter ended with a net loss of $30.7M, narrower than the previous quarter's $44.0M loss.
Operating cash flow was −$21.9M. Non-cash charges added back $341K of depreciation and $1.6M of share-based compensation. Working capital and other items added $6.9M. Capital expenditures of $90K exceeded it, leaving free cash flow of −$21.9M.
Questions
What was ADC Therapeutics SA's revenue in the fourth quarter 2024?
ADC Therapeutics SA (ADCT) reported revenue of $16.9M for the fourth quarter 2024 (Q4 2024), +0.7% from a year earlier and -8% from the quarter before.
Was ADC Therapeutics SA profitable in the fourth quarter 2024?
Operating loss was $32.4M (-191.8% of revenue) and net loss $30.7M.